The Challenge
A leading multinational pharmaceutical company sought to align its operational workflows with their bold strategic goals, including accelerating clinical pipelines, achieving operational excellence, and equipping their teams with innovative digital solutions. At the center of their challenge was an inefficient and manual-driven process creation workflow, integral to clinical trial execution. Each new process map required up to 16 weeks of effort, involving time-intensive cross-functional collaboration, meetings, and iterative reviews.
While thorough, this approach taxed internal resources. Recognizing the potential of generative AI (GenAI) to transform their ways of working, the organization needed a robust, forward-thinking strategy to validate its potential—not just to automate steps, but to reshape how work gets done.
Eager to maintain their competitive edge, they partnered with Point B to explore operationalizing the use of GenAI in process creation while ensuring compliance, scalability, and accuracy.
The Opportunity
Drawing on our deep expertise in life sciences and digital innovation, we helped our client envision a new way forward—one where GenAI didn’t just automate tasks but unlocked entirely new efficiencies in clinical process design. By starting with the pharmaceutical’s goals and operational pain points, we pinpointed three critical needs:
- Streamline Process Development: Drastically accelerate steps in the creation and digitization of clinical trial delivery processes.
- Create a Unified System: Consolidate disconnected systems and platforms into an integrated "all-in-one" solution that simplifies drafting and collaboration.
- Deliver Scalable Insights: Implement data-driven solutions to uncover operational opportunities and provide actionable recommendations to scale AI’s role enterprise-wide.
This holistic approach aimed not only to cut drafting timelines but also to fundamentally enhance operational excellence, setting the stage for future AI-powered scalability to new business units.
Our Approach
Point B designed and executed a rapid Proof of Concept (PoC) that demonstrated the feasibility and power of GenAI workflows in tackling these operational challenges. Based on the results of the PoC, the solution advanced, integrating cutting-edge technology developed through an agile methodology, ensuring measurable outcomes grounded in client collaboration and real-world application. Key components of the solution include:
- GenAI Workflows: AI-powered agents act as “virtual assistants” to generate a first draft of process maps and RACIs (Responsibility, Accountability, Consulted, and Informed structures), automating the earliest, labor-intensive steps of process creation.
- Unified Process Digitization Tool: An all-in-one cloud-based application demonstrates potential to replace multiple disconnected systems, streamline collaboration, reduce hand-offs and steps to move from draft to production-ready state.
- Centering Human-in-the-Loop Oversight: To uphold regulatory standards and the highest operational accuracy, the solution enables human validation of AI activity, ensuring compliance, oversight, and confidence.
- Data-Driven Insights: AI provides suggestions to users on ways to further refine the process drafts, along with bigger picture operational insights, drawn from observations about existing processes and data.
Working closely with operational, clinical, and R&D teams, Point B deployed a sandbox testing environment to capture and integrate user feedback and validate AI activity. This approach ensures the launch solution meets users’ needs while aligning with the company’s overarching strategic goals.
By operationalizing GenAI into their workflows, our client is poised for faster process mapping and improved clinical trial execution.
Projected Impact
Initial results from the PoC, combined with projected outcomes from a fully operationalized solution, point to a transformative opportunity:
- 70% reduction in process drafting time.
- Enable the organization to complete three processes in the time it currently takes to deliver one.
- Empower employees to focus on highest-value activities, optimizing process quality.
- Deliver greater consistency and accuracy in process execution, ultimately improving trial outcome.
- Eliminate the need to toggle between multiple systems, simplifying process creation and fostering collaboration.
- Support future expansion across additional business units, setting the foundation for broader adoption and impact.
By operationalizing GenAI into their workflows, our client is poised for faster process mapping and improved clinical trial execution. This initiative doesn’t just improve business processes; it exemplifies industry leadership, proving how companies can harness advanced AI to drive measurable business value from compliance to efficient trial delivery.
Looking Ahead
The success of this PoC reveals a broader opportunity for enterprises to leverage generative AI strategically. By focusing on human-AI collaboration, organizations can not only achieve operational excellence but also empower teams for higher-impact work.
We continue to partner with the pharmaceutical company to refine the solution and prepare for business adoption, while exploring additional AI applications that promise to deliver even greater business transformation.
Are you ready to explore the untapped potential of generative AI? Whether it’s launching a pilot or expanding an AI adoption roadmap, Point B can guide you at every step. Contact us today to accelerate your path to innovation and drive smarter, more efficient decision-making.
RELATED INDUSTRIES
RELATED SOLUTIONS
